# MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

> **NCT00660543** · NA · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 14 (actual)

## Conditions studied

- Adult Brain Glioblastoma

## Interventions

- **DRUG:** Gadolinium
- **DRUG:** Ferumoxytol Non-Stoichiometric Magnetite
- **OTHER:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **OTHER:** Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- **OTHER:** Diffusion Weighted Imaging
- **OTHER:** MRI-Based Angiogram

## Key facts

- **NCT ID:** NCT00660543
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660543, "MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00660543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*